Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 25, 2026 06:00 ET | Source: Oblenio Bio, Inc.

Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development

Oblenio's Series B round was led by Pfizer Ventures, with participation from new investors Deep Track Capital, GV, and founding investor, Aditum Bio.